NOV 08, 2017 12:00 PM PST

Combined immunohistochemistry and RNA in situ hybridization to elucidate tumor molecular heterogeneity in prostate cancer

Speaker
  • Associate Scientist, Henry Ford Health System
    Biography
      Dr. Palanisamy completed his undergraduate and graduate studies at the University of Madras, India, and is currently an Associate/Senior Scientist at the Henry Ford Health System. He also holds an adjunct faculty appointment with the Michigan Center for Translational Pathology (MCTP) at the University of Michigan. His current research program is focused on the discovery of cancer biomarkers in lymphomas and solid cancers. During his post-doctoral research at the Memorial Sloan-Kettering Cancer Center, Dr. Palanisamy's work contributed to the discovery of recurrent gene fusions in follicular and diffuse large B-cell lymphomas. He was the founding Director of Research and Development at the Cancer Genetics, Inc (CGIX), where he introduced novel approaches to develop diagnostic reagents targeting chromosomal translocations in cancer. Dr. Palanisamy pioneered the application of next generation sequencing technology for transcriptome sequencing and discovered novel "druggable" gene fusions in prostate cancer, gastric cancer, and melanoma (Palanisamy et al., Nat Med 2010). His current research aims to understand the molecular basis of tumor heterogeneity in solid cancers, with particular focus on prostate cancer, and its impact in early diagnosis, response to treatment, and clinical outcome.

    Abstract

    Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors are highly heterogeneous and there are many studies evaluating the molecular profile or ‘fingerprint’ of prostate cancer.  Conventional analysis reviews the protein expression of key markers via serum analysis and immunohistochemistry (IHC) of the biopsy.  In this presentation we will review how RNA in situ hybridization (ISH) analysis of prostate cancer can unravel the molecular heterogeneity of the tumor, identify molecular subsets and detect key fusions and mutations of the RNA.  We will also present a comparison of IHC and ISH technology and the combination of dual color IHC and dual color ISH can be used to enhance simultaneous evaluation of DNA, RNA and protein, revealing the molecular profile of prostate cancer.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    AUG 18, 2020 10:00 AM PDT
    C.E. CREDITS
    AUG 18, 2020 10:00 AM PDT
    DATE: August 18, 2020 TIME: 10:00am PT Get deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the n...
    NOV 10, 2020 7:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    NOV 10, 2020 7:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    Loading Comments...
    Show Resources
    Attendees
    • See more